PRISM Mid-Day Movers: Contract Breaches and Patent Allowances Spell Different Fates For AI and Weight Loss Indices

ReShape Lifesciences Surges 32% on New Diabetes Neuromodulation Patent
ReShape Lifesciences Inc. (RSLS) soared 32% to lead the PRISM Emerging Weight Loss Index after announcing it received a new U.S. patent allowance tied to its proprietary Diabetes Neuromodulation platform. The patent, which extends protection through August 2037, covers a unique low-energy signal delivery method that can regulate blood glucose while consuming one-tenth the energy of conventional neuromodulation devices.

The technology, based on ReShape's vBloc(TM) vagus nerve platform, aims to treat Type 2 diabetes through targeted vagal nerve modulation. Preclinical trials have shown the same efficacy as standard continuous stimulation, while being compatible with widely available implantable pulse generators--making the system potentially more affordable and commercially viable.

CEO Paul Hickey stated, "The recent allowance of this patent further reinforces the promise of our groundbreaking Neuromodulation technology. Designed to personalize diabetes management, this innovation has demonstrated the potential to reduce reliance on medications by optimizing glucose control."

This development comes as ReShape prepares to its assets to Biorad Medisys Pvt. Ltd., under an asset purchase agreement announced earlier this year. The deal includes ReShape's Lap-Band(R), Obalon(R), and DBSN(TM) systems (excluding cash).

Roadzen Drops 7% After Filing $19.5M Lawsuit Over Contract Breach
Shares of Roadzen Inc. (RDZN) fell more than 7%, dragging down the PRISM Emerging NextGen Tech & AI Index, following news that the AI-driven mobility and insurance tech company filed a multi-million dollar lawsuit against Meteora Capital Partners and affiliated entities. Filed in Florida, the suit alleges that Meteora violated the terms of a 2023 Forward Purchase Agreement by selling over 1.8 million shares without remitting proceeds or providing required disclosures.

Roadzen is seeking approximately $19.5 million in damages, citing what CEO Rohan Malhotra described as a "willful breach of contract and a serious violation of trust." The complaint also alleges that Meteora made misleading statements about its holdings to avoid payment obligations.

Other PRISM Mid-Day Movers:

• Rezolute, Inc. (RZLT) up 17.47%
• Terns Pharmaceuticals, Inc. (TERN) up 15.00%
• Taysha Gene Therapies, Inc. (TSHA) up 14.92%
• Clearmind Medicine Inc. (CMND) down 13.83%

The post PRISM Mid-Day Movers: Contract Breaches and Patent Allowances Spell Different Fates For AI and Weight Loss Indices appeared first on PRISM MarketView.

COMTEX_464775125/2927/2025-04-21T13:30:40